Figure 2
Relationships between clinical parameters and serum concentrations of CCL-18 and IL-23 in COPD patients. (A) The serum CCL-18 concentrations were higher in COPD patients of GOLD 3–4 than in those of GOLD 1–2 (p < 0.001). (B) The serum CCL-18 concentrations were higher in COPD patients with mMRC score of 4 than in those with mMRC score of 2–3 (p < 0.001). (C) The serum CCL-18 concentrations were higher in COPD patients with longer clinical history than in those with shorter clinical history (p < 0.001). (D) The serum IL-23 concentrations were higher in COPD patients of GOLD 3–4 than in those of GOLD 1–2 (p < 0.001). (E) The serum IL-23 concentrations were higher in COPD patients with mMRC score of 4 than in those with mMRC score of 2–3 (p < 0.001). (F) The serum IL-23 concentrations were higher in COPD patients with longer clinical history than in those with shorter clinical history (p < 0.001). COPD, chronic obstructive pulmonary disease; CCL-18, chemokine (C–C Motif) ligand 18; IL-23, interleukin 23; M ± SD, mean ± standard deviation; GOLD, Global Initiative for Chronic Obstructive Lung Disease; mMRC, modified british medical research council.
